|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although BRAF(V600E) mutation is associated with adverse clinical outcomes in patients with colorectal cancer (CRC), response and resistance mechanisms for therapeutic BRAF(V600E) inhibitors remains poorly understood.
|
26750638 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In protein extracts (2 mg) from 11 CRC tissue specimens, the MRM assay could measure WT BRAF in all 11 cases (0.32-1.66 ng) and the V600E BRAF in two cases (0.1-0.13 ng; mutant-to-WT ratio, 0.16-0.17).
|
27497007 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The aim of this study was to evaluate the concordance between the BRAF (V600E) mutation test and immunohistochemistry (IHC) and to evaluate the diagnostic accuracy of BRAF IHC for colorectal cancer (CRC) through a systematic review, meta-analysis, and diagnostic test accuracy review.
|
27197524 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
|
26787892 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib.
|
26810733 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Our data show that IHC could be used in routine clinical practice as a screening method for BRAF V600E mutant protein detection in CRC patients.
|
27569082 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We screened 535 formalin-fixed paraffin-embedded CRC tissue samples for the BRAF V600E mutation, and selected 7 BRAF-mutated and 7 KRAS-mutated CRCs that were tumor size, stage, and microsatellite status-matched.
|
27082577 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Sporadic MSI CRC often harbours BRAF(V600E); however, no consistent data exist regarding targeted treatment approaches in BRAF(wt) MSI CRC.
|
26001389 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutated group that includes defective DNA mismatch repair with microsatellite instability and POLE mutations in ∼15%, containing multiple frameshifted genes and BRAF(V600E); (2) nonhypermutated group with multiple somatic copy number alterations and aneuploidy in ∼85%, containing oncogenic activation of KRAS and PIK3CA and mutation and loss of heterozygosity of tumor suppressor genes, such as APC and TP53; (3) CpG island methylator phenotype CRCs in ∼20% that overlap greatly with microsatellite instability CRCs and some nonhypermutated CRCs; and (4) elevated microsatellite alterations at selected tetranucleotide repeats in ∼60% that associates with metastatic behavior in both hypermutated and nonhypermutated groups.
|
26216840 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In this study, we used an automated immunohistochemistry (IHC) staining coupled with mouse monoclonal anti-BRAF V600E (VE1) primary antibody to screen the BRAF V600E mutation in 779 tumor cases, including 611 colorectal carcinomas (CRC), 127 papillary thyroid carcinomas (PTC) and 41 malignant melanomas.
|
25784606 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In vitro studies using CRC cell lines showed an association between MGL ligand expression and the presence of BRAF(V600E).
|
26172302 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
To understand how oncogenic B-Raf contributes to carcinogenesis, in particular to aspects other than cellular proliferation and survival, we generated three isogenic human colorectal carcinoma cell line models in which we can dynamically modulate the expression of the B-Raf(V600E) oncoprotein.
|
25381152 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The patient with SSL as index lesions who developed CRC harbored V600E BRAF mutation in both index lesion and the carcinoma.
|
25708741 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia.
|
25862899 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome.
|
26160848 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600-601E, which has analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a prognostic marker for colorectal cancer (CRC).
|
25636897 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The prevalence of dMMR and BRAF V600E in Thai sporadic CRC patients was 15% and 11%, respectively.
|
25624727 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is specifically associated with sporadic MSI+ CRCs with methylated MLH1, but is not associated with Lynch syndrome-related CRCs.
|
25701956 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.
|
26208524 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Lung adenocarcinomas showed significantly higher non-p.V600E mutations (86%) than did colorectal cancers (23%) and melanomas (34%).
|
26386083 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal cancers that are hallmarked by a BRAF V600E mutation and a methylator phenotype, compared to traditional pathway cancers that are BRAF wild type.
|
25613750 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We evaluated miR-31-5p expression and gene mutations [KRAS (codon 61 or 146), NRAS (codon 12, 13, or 61), and BRAF (V600E)] in the EGFR downstream pathway in 102 CRC patients harboring KRAS (codon 12 or 13) wild-type who were treated with anti-EGFR therapeutics.
|
25472647 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
|
26496026 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
|
25714871 |
2015 |